快速释放瓣膜用于单纯主动脉瓣反流的早期结果
本研究回顾性分析2017至2022年22例因单纯主动脉瓣反流接受快速释放瓣膜植入的患者,并与同期77例单纯主动脉瓣狭窄患者比较。两组均无术中及术后瓣膜修整,跨瓣压差相当,无瓣周漏;快速释放组术后起搏器植入率为0%,传统瓣膜置换组为1.3%。结论提示快速释放瓣膜可安全用于主动脉瓣反流患者。
要点
- 快速释放瓣膜可用于无钙化的单纯主动脉瓣反流患者。
- 术后起搏器植入率快速释放组0%,传统瓣膜置换组1.3%。
- 两组跨瓣压差相当且无瓣周漏,无瓣膜修整。
核心结论
- 快速释放瓣膜可安全应用于单纯主动脉瓣反流患者,即使瓣膜无钙化。
- 该技术扩展了外科医生的治疗手段,尤其适用于需广泛手术、节省主动脉阻断时间有益的患者。
研究设计与样本
- 回顾性分析2014至2022年444例快速释放瓣膜植入,其中2017至2022年22例用于单纯主动脉瓣反流。
- 反流队列与同期77例因单纯主动脉瓣狭窄接受快速释放瓣膜植入的患者进行比较。
- 分析主要临床结局包括起搏器植入、死亡、主要不良心脑血管事件(MACCE)及再次手术需求。
主要发现
- 两组均无术中及术后瓣膜修整。
- 跨瓣压差两组相当:反流组ΔPmean/max 7.1/13.3 mmHg,狭窄组7.9/14.7 mmHg。
- 两组均无瓣周漏。
- 术后起搏器植入率:快速释放组0%,传统瓣膜置换组1.3%。
临床怎么用
- 对于单纯主动脉瓣反流患者,可考虑使用快速释放瓣膜,尤其适用于需广泛手术、节省主动脉阻断时间有益的情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Surgical aortic valve implantation remains the therapeutic gold standard for aortic valve regurgitation. Due to annular dilatation and lack of calcification, transcatheter aortic valve replacement is not recommended. Although rapid deployment valves allow faster implantation and excellent haemodynamics, they are currently not recommended for patients with aortic valve regurgitation. This study retrospectively analysed the use of rapid deployment prostheses in patients with pure aortic valve regurgitation. METHODS: From 2014 to 2022, 444 rapid deployment valves were implanted. Since 2017 until 2022, 22 were used for patients with pure aortic valve regurgitation. This cohort was compared to 77 patients who had undergone rapid deployment valve implantation for pure aortic stenosis during the same time period. Both cohorts were analysed for major clinical outcomes, including pacemaker implantation, mortality, major adverse cardiovascular and cerebrovascular events (MACCE), and the need for redo surgery. RESULTS: In both groups, no valve intraoperative and postoperative valve revisions were required. Transvalvular gradients were comparable between the groups (ΔPmean/max 7.1/13.3 mmHg in the aortic valve regurgitation and 7.9/14.7 mmHg in the AS cohort), and there were no paravalvular leaks. The postoperative pacemaker implantation rate was 0% for the rapid deployment group and 1.3% for the conventional valve replacement group. CONCLUSIONS: These results suggest that rapid deployment valves can be safely applied for the treatment of patients with aortic valve regurgitation, even in the absence of calcification. This expands the surgeon's armamentarium and can be especially useful in patients requiring extensive surgery where saving aortic cross-clamp time may be especially beneficial.
引用
- von der Linden J, Vlachea P, Kolos O, et al. Promising early outcomes in surgical aortic valve replacement utilizing the rapid deployment approach for isolated aortic valve regurgitation. Interdiscip Cardiovasc Thorac Surg. 2025. PMID: 40581759. doi:10.1093/icvts/ivaf147
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。